In summary, findings in this study demonstrate significant in vitro and in vivo efficacy of CDK9 inhibition in esophageal adenocarcinoma and identify that CDK9 regulates MCL-1 transcription by inhibiting binding of HIF-1alpha to MCL-1 promoter. This evidence concerns the gene CDK9 and esophageal adenocarcinoma.